Business Wire

Regula Rolls Out Personal Data Masking Across All Solutions for Easier Privacy Compliance

27.5.2025 13:30:00 CEST | Business Wire | Press Release

Share

To help organizations stay ahead of tightening data privacy regulations, Regula, a global developer of identity verification solutions, has extended its personal data masking functionality to Regula Forensic Studio (RFS), software that powers forensic devices. This new update helps document experts protect personal data with a single click, meeting growing privacy demands without disrupting workflows.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527916240/en/

Regula adds one-click personal data masking to all ID verification tools. With a single click on “Depersonalize” in Regula Forensic Studio, personal information like names, photos, and ID numbers is automatically blurred—helping businesses meet GDPR and global privacy standards. (Photo: Regula) 

Already available in Regula Document Reader SDK, the personal data hiding feature is now also a part of the RFS toolset used by border control officers, forensic professionals, and law enforcement agencies. This means the entire Regula ecosystem—from real-time ID verification to in-depth forensic analysis—now supports robust privacy controls natively.

This enhancement comes at a time when compliance is not just a checkbox, but a business-critical imperative. According to Regula's global survey, 28% of companies cite regulatory compliance as the primary reason for implementing identity verification solutions. Among large enterprises, that figure rises to 35%.

The new capability allows document experts to easily blur or hide personally identifiable information (PII), such as names, photos, and ID numbers, directly within forensic workflows. This ensures that sensitive data is handled responsibly while meeting strict global requirements like GDPR, CCPA, and others.

“Regula’s forensic tools are trusted by professionals who handle the most sensitive identity documents, so privacy and compliance can’t be an afterthought,” said Ihar Kliashchou, Chief Technology Officer at Regula. “With one-click data masking now built into our ID verification tools, experts can instantly anonymize personal information during analysis, enabling secure, compliant workflows for audits, training, or database creation, without sacrificing speed or accuracy.”

What else is new in Regula Forensic Studio?

In addition to the personal data masking feature, the latest RFS release includes 40+ updates focused on speed, customization, and forensic precision:

  • New analysis tools: Yellow dot analysis for tracing document origins and detecting unauthorized duplicates.
  • Smarter imaging: Per-light-source gamma correction and full-spectrum HDR imaging (not just UV), improving clarity across all materials.
  • Streamlined collaboration: Video screen capture and camera recording capabilities support team training and case reviews.
  • Faster insights: Hyperspectral imaging is now 20% faster without compromising detail.
  • Improved digital zoom: Expanded up to 16x for detailed inspections.
  • Visual reporting: Ability to generate composite images under varied lighting, ideal for expert reports or courtroom presentations.
  • Integrated workflows: Automated document searches in the Information Reference System (IRS) after MRZ reading to reduce manual steps.
  • Flexible video modes: Three options for different examination tasks—real-time viewing without frame skipping, high-resolution capture, and an expanded A4 field-of-view mode.
  • Wider OS compatibility: Now supports Rocky and Debian Linux distributions, expanding deployment options.

For more information about Regula Forensic Studio and its latest features, please visit Regula's official website.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250527916240/en/

Contacts

Kristina – ks@regulaforensics.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye